TrialDiabetes, obesity & metabolism2025

Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third-line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP-4 inhibitors: A multicentre, phase 4 randomized controlled trial.

Yun Kyung Cho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.